Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients (HEPCAT)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT01125189
First received: May 17, 2010
Last updated: September 23, 2015
Last verified: September 2015
Results First Received: August 13, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Hepatitis C Virus
Interventions: Drug: Daclatasvir
Drug: Placebo
Drug: peg-interferon alfa-2a
Drug: ribavirin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were enrolled at 64 sites in 11 countries.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
A total of 558 participants were enrolled in this study, and 395 participants were randomized and treated.

Reporting Groups
  Description
Daclatasvir (20 mg) + Peg-interferon Alfa-2a + Ribavirin Participants received daclatasvir tablets 20 mg orally, once daily with pegylated-interferon alfa-2a solution for injection 180 µg per 0.5 mL subcutaneously, once weekly, and ribavirin tablets 1000-1200 mg orally, twice daily for a total duration of 12 weeks. After Week 12, additional treatment was provided with interferon and ribavirin for a total of 24 or 48 weeks of therapy depending on whether or not the participant achieved an on-treatment response as defined in protocol.
Daclatasvir (60 mg) + Peg-interferon Alfa-2a + Ribavirin Participants received daclatasvir tablets 60 mg orally, once daily with pegylated-interferon alfa-2a solution for injection 180 µg per 0.5 mL subcutaneously, once weekly, and ribavirin tablets 1000-1200 mg orally, twice daily for a total duration of 12 weeks. After Week 12, additional treatment was provided with interferon and ribavirin for a total of 24 or 48 weeks of therapy depending on whether or not the participant achieved an on-treatment response as defined in protocol.
Placebo + Peg-interferon Alfa-2a + Ribavirin Participants received placebo matched with daclatasvir tablets orally, once daily with pegylated-interferon alfa-2a solution for injection 180 µg per 0.5 mL subcutaneously, once weekly, and ribavirin tablets 1000-1200 mg orally, twice daily, for a total duration of 24 weeks and pegylated-interferon alfa-2a and ribavirin, for a total duration of 48 weeks.

Participant Flow for 2 periods

Period 1:   Treatment Period
    Daclatasvir (20 mg) + Peg-interferon Alfa-2a + Ribavirin   Daclatasvir (60 mg) + Peg-interferon Alfa-2a + Ribavirin   Placebo + Peg-interferon Alfa-2a + Ribavirin
STARTED   159   158   78 
COMPLETED   128   123   37 
NOT COMPLETED   31   35   41 
Lack of Efficacy                15                18                25 
Adverse Event                7                8                8 
Withdrawal by Subject                3                1                1 
Death                1                0                0 
Lost to Follow-up                1                2                1 
Poor compliance/noncompliance                0                1                0 
Participants requested to discontinue                1                3                4 
Other reasons                1                1                0 
Completed 24 week treatment period only                2                1                2 

Period 2:   Follow up Period
    Daclatasvir (20 mg) + Peg-interferon Alfa-2a + Ribavirin   Daclatasvir (60 mg) + Peg-interferon Alfa-2a + Ribavirin   Placebo + Peg-interferon Alfa-2a + Ribavirin
STARTED   152 [1]   153 [1]   74 [1] 
COMPLETED   132   138   58 
NOT COMPLETED   20   15   16 
Withdrawal by Subject                3                2                5 
Death                1                0                0 
Lost to Follow-up                12                9                6 
Other reasons                4                4                5 
[1] All participants who received treatment continued in the follow-up phase.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Daclatasvir (20 mg) + Peg-interferon Alfa-2a + Ribavirin Participants received daclatasvir tablets 20 mg orally, once daily with pegylated-interferon alfa-2a solution for injection 180 µg per 0.5 mL subcutaneously, once weekly, and ribavirin tablets 1000-1200 mg orally, twice daily for a total duration of 12 weeks. After Week 12, additional treatment was provided with interferon and ribavirin for a total of 24 or 48 weeks of therapy depending on whether or not the participant achieved an on-treatment response as defined in protocol.
Daclatasvir (60 mg) + Peg-interferon Alfa-2a + Ribavirin Participants received daclatasvir tablets 60 mg orally, once daily with pegylated-interferon alfa-2a solution for injection 180 µg per 0.5 mL subcutaneously, once weekly, and ribavirin tablets 1000-1200 mg orally, twice daily for a total duration of 12 weeks. After Week 12, additional treatment was provided with interferon and ribavirin for a total of 24 or 48 weeks of therapy depending on whether or not the participant achieved an on-treatment response as defined in protocol.
Placebo + Peg-interferon Alfa-2a + Ribavirin Participants received placebo matched with daclatasvir tablets orally, once daily with pegylated-interferon alfa-2a solution for injection 180 µg per 0.5 mL subcutaneously, once weekly, and ribavirin tablets 1000-1200 mg orally, twice daily, for a total duration of 24 weeks and pegylated-interferon alfa-2a and ribavirin, for a total duration of 48 weeks.
Total Total of all reporting groups

Baseline Measures
   Daclatasvir (20 mg) + Peg-interferon Alfa-2a + Ribavirin   Daclatasvir (60 mg) + Peg-interferon Alfa-2a + Ribavirin   Placebo + Peg-interferon Alfa-2a + Ribavirin   Total 
Overall Participants Analyzed 
[Units: Participants]
 159   158   78   395 
Age, Customized 
[Units: Participants]
       
<65 years   154   154   77   385 
≥65 years   5   4   1   10 
Gender 
[Units: Participants]
       
Female   52   55   23   130 
Male   107   103   55   265 
Hepatitis C Virus RNA Distribution 
[Units: Participants]
       
<800,000 IU/mL   26   35   17   78 
≥800,000 IU/mL   133   123   61   317 
IL-28B Genotype 
[Units: Participants]
       
CC genotype   53   44   23   120 
CT genotype   82   86   38   206 
TT genotype   17   18   11   46 
Missing   7   10   6   23 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With Extended Rapid Virologic Response (eRVR)   [ Time Frame: Weeks 4 and 12 ]

2.  Primary:   Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With Sustained Virologic Response (SVR24)   [ Time Frame: Follow-up Week 24 ]

3.  Primary:   Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), and Who Died   [ Time Frame: From start of study treatment (day 1) up to follow-up Week 48 ]

4.  Secondary:   Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With Rapid Virologic Response (RVR)   [ Time Frame: Week 4 ]

5.  Secondary:   Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With Complete Early Virologic Response (cEVR)   [ Time Frame: Week 12 ]

6.  Secondary:   Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With 12-week Sustained Virologic Response (SVR12)   [ Time Frame: Follow-up Week 12 ]

7.  Secondary:   Percentage of Resistant Variants Associated With Virologic Failure   [ Time Frame: Follow-up Week 48 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Bristol-Myers Squibb Study Director
Organization: Bristol-Myers Squibb
e-mail: Clinical.Trials@bms.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT01125189     History of Changes
Other Study ID Numbers: AI444-010
2010-018295-24 ( EudraCT Number )
Study First Received: May 17, 2010
Results First Received: August 13, 2015
Last Updated: September 23, 2015
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration
Australia: National Health and Medical Research Council
Canada: Health Canada
Canada: Regulatory Affairs Division Office of Clinical Trials Therapeutic Products Directorate
Denmark: Danish Dataprotection Agency
Denmark: Danish Medicines Agency
Denmark: The Danish National Committee on Biomedical Research Ethics
Egypt: National Ethic Committee
Egypt: Ministry of Health, Drug Policy and Planning Center
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Ministry of Health
Germany: Federal Institute for Drugs and Medical Devices
Israel: Israeli Health Ministry Pharmaceutical Administration
Italy: Ministry of Health
Italy: National Bioethics Committee
Italy: National Institute of Health
Italy: National Monitoring Centre for Clinical Trials - Ministry of Health
Italy: The Italian Medicines Agency
Mexico: Federal Commission for Sanitary Risks Protection
Sweden: Medical Products Agency
Sweden: The National Board of Health and Welfare
Sweden: The Swedish Data Inspection Board
Sweden: Central Ethics Board
United States: Food and Drug Administration